Related references
Note: Only part of the references are listed.Comparative Effectiveness of Immunosuppressants and Biologics for Inducing and Maintaining Remission in Crohn's Disease: A Network Meta-analysis
Glen S. Hazlewood et al.
GASTROENTEROLOGY (2015)
Splitting a Therapeutic Dose of Thioguanine May Avoid Liver Toxicity and Be an Efficacious Treatment for Severe Inflammatory Bowel Disease: A 2-Center Observational Cohort Study
Polychronis Pavlidis et al.
INFLAMMATORY BOWEL DISEASES (2014)
HLA-DQA1-HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants
Graham A. Heap et al.
NATURE GENETICS (2014)
A trial of mercaptopurine is a safe strategy in patients with inflammatory bowel disease intolerant to azathioprine: an observational study, systematic review and meta-analysis
N. A. Kennedy et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2013)
Review article: the association between nodular regenerative hyperplasia, inflammatory bowel disease and thiopurine therapy
C. O. Musumba
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2013)
Use of Azathioprine and the Risk of Cancer in Inflammatory Bowel Disease
Bjorn Pasternak et al.
AMERICAN JOURNAL OF EPIDEMIOLOGY (2013)
A novel mouse model of veno-occlusive disease provides strategies to prevent thioguanine-induced hepatic toxicity
Iulia Oancea et al.
GUT (2013)
Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: Current management
Axel Dignass et al.
JOURNAL OF CROHNS & COLITIS (2012)
Prolonged thioguanine therapy is well tolerated and safe in the treatment of ulcerative colitis
Dirk P. van Asseldonk et al.
DIGESTIVE AND LIVER DISEASE (2011)
Increased Risk for Nonmelanoma Skin Cancers in Patients Who Receive Thiopurines for Inflammatory Bowel Disease
Laurent Peyrin-Biroulet et al.
GASTROENTEROLOGY (2011)
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management
A. Dignass et al.
JOURNAL OF CROHNS & COLITIS (2010)
Novel pharmacogenetic markers for treatment outcome in azathioprine-treated inflammatory bowel disease
M. A. Smith et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2009)
6-Thioguanine therapy in Crohn's disease-Observational data in Swedish patients
S. H. C. Almer et al.
DIGESTIVE AND LIVER DISEASE (2009)
Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study
Laurent Beaugerie et al.
LANCET (2009)
Absence of nodular regenerative hyperplasia after low-dose 6-thioguanine maintenance therapy in inflammatory bowel disease patients
N. K. H. de Boer et al.
DIGESTIVE AND LIVER DISEASE (2008)
Further Experience with the Use of 6-Thioguanine in Patients with Crohn's Disease
Azhar Ansari et al.
INFLAMMATORY BOWEL DISEASES (2008)
Histopathology of liver biopsies from a thiopurine-naive inflammatory bowel disease cohort: Prevalence of nodular regenerative hyperplasia
Nanne K. H. De Boer et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2008)
Nodular regenerative hyperplasia in patients with inflammatory bowel disease treated with azathioprine
G. Vernier-Massouille et al.
GUT (2007)
Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine
Miles P. Sparrow et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2007)
Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease
P Rutgeerts et al.
GASTROINTESTINAL ENDOSCOPY (2006)
Pharmacokinetics of 6-thioguanine in patients with inflammatory bowel disease
LJJ Derijks et al.
THERAPEUTIC DRUG MONITORING (2006)
A multicenter assessment of liver toxicity by MRI and biopsy in IBD patients on 6-thioguanine
J Seiderer et al.
JOURNAL OF HEPATOLOGY (2005)
6-thioguanine can cause serious liver injury in inflammatory bowel disease patients
MC Dubinsky et al.
GASTROENTEROLOGY (2003)
Leucocyte versus erythrocyte thioguanine nucleotide concentrations in children taking thiopurines for acute lymphoblastic leukaemia
DL Lancaster et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2002)
Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease
PW Lowry et al.
GUT (2001)
An open-label pilot study using thioguanine as a therapeutic alternative in Crohn's disease patients resistant to 6-mercaptopurine therapy
MC Dubinsky et al.
INFLAMMATORY BOWEL DISEASES (2001)